What question did this study set out to answer?

The trial aims to evaluate whether the combination treatment of fluconazole and flucytosine reduces all-cause mortality compared to fluconazole alone for adults with advanced HIV disease and antigenaemia.

March 26, 2026TrialsOpen Access

Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial

View Full Paper

Ask AI

Bookmark

Authors

KMKyla MurphyUniversity of the Witwatersrand JNJeremy NelUniversity of the Witwatersrand MMMahomed-Yunus Moosa

Discussion

Member takes

Implication

This multi-centre trial compares fluconazole plus flucytosine to fluconazole alone for reducing mortality in adults with HIV-associated antigenaemia, suggesting improved outcomes.

Key Points

The trial aims to evaluate whether the combination treatment of fluconazole and flucytosine reduces all-cause mortality compared to fluconazole alone for adults with advanced HIV disease and antigenaemia.
Conducting a multi-centre, open-label phase III randomised-controlled trial in South Africa and Tanzania.
Enrolling 600 participants with a blood CrAg-positive test but no meningitis evidence.
Administering 14 days of fluconazole (1200 mg/day) plus flucytosine (100 mg/kg/day) versus fluconazole alone (1200 mg/day).
Assessing primary and secondary outcomes at 6 months, including mortality and incidence of symptomatic meningitis.
Combination treatment with fluconazole and flucytosine is being evaluated for effectiveness against fluconazole alone.
Expected to observe a significant reduction in mortality rates based on primary endpoint analysis.
Secondary outcomes will evaluate incidence rates of cryptococcal meningitis and adverse events.

Cite This Study

Murphy et al. (2026) studied this question.

synapsesocial.com/papers/69c4cdb6fdc3bde44891a5a5 https://doi.org/10.1186/s13063-026-09520-x

View Full Paper

Ask AI

Bookmark

Implication

This multi-centre trial compares fluconazole plus flucytosine to fluconazole alone for reducing mortality in adults with HIV-associated antigenaemia, suggesting improved outcomes.

Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider